MAM
MLYS icon

Martingale Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Martingale Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,960
Closed -$238K – 828
2025
Q1 		$238K Sell
14,960
-5
-0% -$58 0.01% 715
2024
Q4 		$184K Hold
14,965
– – ﹤0.01% 742
2024
Q3 		$181K Buy
+14,965
New +$181K ﹤0.01% 768

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Martingale Asset Management's MLYS Position: Q2 2025 in Review

Martingale Asset Management sold out of Mineralys Therapeutics (MLYS) in Q2 2025, closing a stake of 14,960 shares — an estimated $238K sold.

Martingale Asset Management first reported a position in MLYS in Q3 2024 and held it in 3 quarters. The position peaked at $238K in Q1 2025. 165 funds tracked by Wall St. Rank hold MLYS as of Q2 2025.

  • Martingale Asset Management reported no remaining Mineralys Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Martingale Asset Management sold 14,960 Mineralys Therapeutics shares in Q2 2025, an estimated $238K.
  • Martingale Asset Management first reported a position in Mineralys Therapeutics in Q3 2024 and held it in 3 quarters.
  • Martingale Asset Management's Mineralys Therapeutics position peaked at $238K in Q1 2025.
  • 165 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2025.

Based on Martingale Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.